AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ORTHOCELL LTD

0.765

+0.0101.32%

Volume:399.75K

Turnover:290.33K

Market Cap:207.38M

PE:-14.67

High:0.765

Open:0.765

Low:0.715

Close:0.755

52wk High:1.600

52wk Low:0.700

Shares:271.09M

Float Shares:194.08M

Volume Ratio:1.81

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.052

EPS(LYR):-0.038

ROE:-41.06%

ROA:-20.97%

PB:5.04

PE(LYR):-19.94

Loading ...

Overview Company News Filings

Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada

MT Newswires Live

Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%

MT Newswires Live

Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says

MT Newswires Live

Stock Track | Orthocell Shares Plummet 8.21% Intraday on Stagnant Quarterly Revenue

Orthocell Says March Quarter Revenue in Line With Prior Quarter; Shares Down 5%

MT Newswires Live

BRIEF-Orthocell Says QTRLY A$3.2 Million Revenue Achieved

Orthocell Ltd - Qtrly a$3.2 Mln Revenue Achieved

THOMSON REUTERS

BUZZ-Australia's Orthocell set for best week since November 2024 on US DoD approval for key product

Stock Track | Orthocell Soars 7.84% Intraday on First Surgical Use of Nerve Repair Product in US Defense Hospital

Orthocell Says First Surgical Case Using Nerve Repair Product in US Department of Defense Hospital Network Completed

MT Newswires Live

Orthocell Ltd-First Surgical Use of Remplir in US Department of Defense

THOMSON REUTERS

Orthocell wins approval to sell Remplir across US DoD, VA hospital networks

BRIEF-Orthocell Ltd Receives Approval For Remplir In 51 Department of Defence Hospitals

Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks

MT Newswires Live

Orthocell Ltd - Receives Approval for Remplir in 51 Dod Hospitals and 170 Va Medical Centres

THOMSON REUTERS

Orthocell Says Proposed US Pharmaceutical Tariffs Not Expected to Apply to Remplir; Shares Up 4%

MT Newswires Live

BRIEF-Orthocell Says US Section 232 Tariffs Not Expected To Affect Remplir

Orthocell Ltd - US Section 232 Tariffs Not Expected to Affect Remplir

THOMSON REUTERS

Bell Potter just put a buy rating on this exciting small-cap ASX stock

Bell Potter Starts Orthocell at Speculative Buy with AU$1.15 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/OCC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","market":"AU","secType":"STK","nameCN":"ORTHOCELL LTD","latestPrice":0.765,"timestamp":1788156720000,"preClose":0.755,"halted":0,"volume":399749,"delay":0,"changeRate":0.013245033112582794,"nameEN":"ORTHOCELL LTD","floatShares":194076512,"shares":271090199,"eps":-0.052151,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"08-31 16:12:00 AEST","open":0.765,"high":0.765,"low":0.715,"amount":290331,"amplitude":0.066225,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.052151,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.755,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.808380410250408,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"OCC.AU","preClose":0.755,"auctionPrice":0.765,"auctionVolume":338,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156601601}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","floatShares":194076512,"roa":"-20.97%","roe":"-41.06%","lyrEps":-0.03837,"volumeRatio":1.808380410250408,"shares":271090199,"dividePrice":0,"high":0.765,"amplitude":0.066225,"preClose":0.755,"low":0.715,"week52Low":0.7,"pbRate":"5.04","psRate":"22.22","week52High":1.6,"institutionHeld":0,"latestPrice":0.765,"eps":-0.052151,"divideRate":0,"volume":399749,"delay":0,"ttmEps":-0.052151,"open":0.765,"prevYearClose":1.085,"prevWeekClose":0.755,"prevMonthClose":0.765,"prevQuarterClose":0.725,"fiveDayClose":0.795,"twentyDayClose":0.705,"sixtyDayClose":0.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCC.AU\",params:#limit:5,,,undefined,":[{"date":"2026-07-13","symbol":"OCC.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1783900800000,"name":null,"time":"","dateTimestamp":1783864800000,"actualEps":null},{"date":"2026-04-20","symbol":"OCC.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776643200000,"name":null,"time":"","dateTimestamp":1776607200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCC.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631503455","title":"Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2631503455","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631503455?lang=en_us&edition=fundamental","pubTime":"2026-04-30 12:31","pubTimestamp":1777523461,"startTime":"0","endTime":"0","summary":"Orthocell  has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630328692","title":"Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630328692","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630328692?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:58","pubTimestamp":1777345106,"startTime":"0","endTime":"0","summary":"Orthocell  said results from an ongoing multi-center post-market clinical follow-up study for its nerve repair product, Remplir, showed an overall treatment success rate of nearly 90%, based on performance data from 66 patients, according to a Tuesday Australian bourse filing.The company said over 90% of motor nerve repairs resulted in functional muscle recovery, while more than 89% of nerve decompression procedures resulted in complete relief or significant improvement of symptoms.The patients were aged 14 to 82 years, and the majority of the procedures were performed in the upper limb. No post-treatment complications or adverse effects were reported.Orthocell's shares jump nearly 4% in recent trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4212","BK7067","OCC.AU","BK7508","POST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629771701","title":"Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2629771701","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629771701?lang=en_us&edition=fundamental","pubTime":"2026-04-21 12:43","pubTimestamp":1776746594,"startTime":"0","endTime":"0","summary":"Orthocell's  fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, Euroz Hartleys said in a note on Tuesday.Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199733288","title":"Stock Track | Orthocell Shares Plummet 8.21% Intraday on Stagnant Quarterly Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1199733288","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199733288?lang=en_us&edition=fundamental","pubTime":"2026-04-20 12:28","pubTimestamp":1776659309,"startTime":"0","endTime":"0","summary":"Orthocell Ltd's stock price plummeted 8.21% during intraday trading on Monday, following the company's quarterly financial update.The biotech company reported revenue of AU$3.2 million for the March...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628528716","title":"Orthocell Says March Quarter Revenue in Line With Prior Quarter; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628528716","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628528716?lang=en_us&edition=fundamental","pubTime":"2026-04-20 12:24","pubTimestamp":1776659078,"startTime":"0","endTime":"0","summary":"Orthocell (ASX:OCC) said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir, according to a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628797217","title":"BRIEF-Orthocell Says QTRLY A$3.2 Million Revenue Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2628797217","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628797217?lang=en_us&edition=fundamental","pubTime":"2026-04-20 09:33","pubTimestamp":1776648826,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says QTRLY A$3.2 Million Revenue AchievedApril 20 (Reuters) - Orthocell Ltd OCC.AX:QTRLY  A$3.2 MILLION REVENUE ACHIEVEDFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN411037:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628791580","title":"Orthocell Ltd - Qtrly  a$3.2 Mln Revenue Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2628791580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628791580?lang=en_us&edition=fundamental","pubTime":"2026-04-20 07:05","pubTimestamp":1776639952,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nFWN411037:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628479221","title":"BUZZ-Australia's Orthocell set for best week since November 2024 on US DoD approval for key product","url":"https://stock-news.laohu8.com/highlight/detail?id=2628479221","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628479221?lang=en_us&edition=fundamental","pubTime":"2026-04-17 11:40","pubTimestamp":1776397205,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell set for best week since November 2024 on US DoD approval for key product** Shares of Australian regenerative medicine co Orthocell OCC.AX rise 7.8% to A$1.1** Co says first surgical case using its nerve repair device Remplir completed in U.S Department of Defense  hospital network** Stock has risen 27.4% so far this week, set for best week since late November 2024** On Wednesday, stock gained 24.1% in its best day in more than a year on news that co has secured approval from U.S. DoD for use of Remplir** Stock down 6% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL6N41007H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137343106","title":"Stock Track | Orthocell Soars 7.84% Intraday on First Surgical Use of Nerve Repair Product in US Defense Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=1137343106","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137343106?lang=en_us&edition=fundamental","pubTime":"2026-04-17 08:02","pubTimestamp":1776384178,"startTime":"0","endTime":"0","summary":"ORTHOCELL LTD's stock soared 7.84% during intraday trading on Friday.The surge followed the company's announcement that the first surgical case using its nerve repair product, Remplir, has been...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628247750","title":"Orthocell Says First Surgical Case Using Nerve Repair Product in US Department of Defense Hospital Network Completed","url":"https://stock-news.laohu8.com/highlight/detail?id=2628247750","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628247750?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:31","pubTimestamp":1776382301,"startTime":"0","endTime":"0","summary":"Orthocell  said that a surgery at a military base hospital in Ohio within the US Department of Defense/Veterans Affairs hospital network was the first surgical case using its nerve repair product, Remplir, according to a Friday Australian bourse filing.The company said that this represented an important step in its US commercialization strategy.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628247359","title":"Orthocell Ltd-First Surgical Use of Remplir in US Department of Defense","url":"https://stock-news.laohu8.com/highlight/detail?id=2628247359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628247359?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:01","pubTimestamp":1776380476,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUE9SXV8K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627263280","title":"Orthocell wins approval to sell Remplir across US DoD, VA hospital networks","url":"https://stock-news.laohu8.com/highlight/detail?id=2627263280","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627263280?lang=en_us&edition=fundamental","pubTime":"2026-04-16 12:09","pubTimestamp":1776312543,"startTime":"0","endTime":"0","summary":"Orthocell secured approval to supply Remplir nerve repair device across US Department of Defense hospital network.Clearance opens access to 51 military hospitals, 170 Veterans Affairs medical centers.Orthocell plans to use distributor network covering 17 states to drive uptake in military, VA systems.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL6d8vxS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476498","title":"BRIEF-Orthocell Ltd Receives Approval For Remplir In 51 Department of Defence Hospitals","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476498","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476498?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:28","pubTimestamp":1776216507,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Ltd Receives Approval For Remplir In 51 Department of Defence HospitalsApril 15 (Reuters) - Orthocell Ltd OCC.AX:ORTHOCELL LTD - RECEIVES APPROVAL FOR REMPLIR IN 51 DOD HOSPITALS AND 170 VA MEDICAL CENTRESSource text: ID:nASX9XYDV7Further company coverage: OCC.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40X16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478227","title":"Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478227","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627478227?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:08","pubTimestamp":1776211731,"startTime":"0","endTime":"0","summary":"Orthocell  said it has secured approval for its Remplir nerve repair device to be used across the US Department of Defense and Veterans Affairs hospital networks, according to a Wednesday Australian bourse filing.The company said it will use its existing US distributor network to target military and VA surgeons operating within these hospital systems, which currently covers 17 states.The approval comes as Orthocell said it is seeing growing evidence of increasing commercialization and revenue momentum in the US market.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420656","title":"Orthocell Ltd - Receives Approval for Remplir in 51 Dod Hospitals and 170 Va Medical Centres","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420656?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:01","pubTimestamp":1776207663,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625935449","title":"Orthocell Says Proposed US Pharmaceutical Tariffs Not Expected to Apply to Remplir; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625935449","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625935449?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:37","pubTimestamp":1775612251,"startTime":"0","endTime":"0","summary":"Orthocell  does not expect its Remplir medical device to be subject to the US administration's proposed Section 232 tariffs under the Trade Expansion Act on pharmaceutical imports, as the device falls outside the tariff's scope, according to a Wednesday Australian bourse filing.The company is confident that its commercial rollout and growth strategy in the US will proceed without disruption or financial impact, the filing added.The company's shares rose around 4% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625962714","title":"BRIEF-Orthocell Says US Section 232 Tariffs Not Expected To Affect Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2625962714","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625962714?lang=en_us&edition=fundamental","pubTime":"2026-04-08 07:54","pubTimestamp":1775606056,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says US Section 232 Tariffs Not Expected To Affect RemplirApril 8 (Reuters) - Orthocell Ltd OCC.AX:US SECTION 232 TARIFFS NOT EXPECTED TO AFFECT REMPLIRFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q1EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625964217","title":"Orthocell Ltd - US Section 232 Tariffs Not Expected to Affect Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2625964217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625964217?lang=en_us&edition=fundamental","pubTime":"2026-04-08 07:06","pubTimestamp":1775603189,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q1EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620298772","title":"Bell Potter just put a buy rating on this exciting small-cap ASX stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2620298772","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620298772?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:52","pubTimestamp":1773870764,"startTime":"0","endTime":"0","summary":"Investors with a high tolerance for risk might want to check out the exciting small-cap ASX stock in this article. That's because the team at Bell Potter has just initiated coverage on it with a bullish view. Which small-cap ASX stock?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/bell-potter-just-put-a-buy-rating-on-this-exciting-small-cap-asx-stock/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/bell-potter-just-put-a-buy-rating-on-this-exciting-small-cap-asx-stock/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","OCC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620237256","title":"Bell Potter Starts Orthocell at Speculative Buy with AU$1.15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620237256","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620237256?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:05","pubTimestamp":1773831933,"startTime":"0","endTime":"0","summary":"Bell Potter Starts Orthocell at Speculative Buy with AU$1.15 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}